New York, June 14, 2026, 07:42 (EDT)
- Ross Stores, Howmet Aerospace, Krystal Biotech, Viking Holdings, and Bloom Energy are on next week’s buy radar, with the recent market bounce and some new bullish chart setups drawing interest.
- Ross and Howmet show the strongest earnings backing. Bloom and Krystal could deliver more upside, but both names trade at higher multiples and come with more risk around results.
Stocks are back in focus for growth and momentum traders as the market heads into next week. Investor’s Business Daily’s weekend screen named Ross Stores, Howmet Aerospace, Krystal Biotech, Viking Holdings, and Bloom Energy as stocks flashing bullish setups or buy signals after the market bounced. A buy signal marks a technical move where demand looks to be topping selling. Shares tend to climb as investors raise future earnings or cash flow bets. They drop when valuation fears, weak outlooks, higher costs, or market pullbacks hit those expectations.
Ross Stores is still seen as the top risk-reward pick on the list, but shares aren’t cheap anymore. The off-price chain last traded at $240.13, up 0.4%, for a P/E of about 33.5. Investors are paying up for every dollar of profit. First-quarter sales at Ross jumped 21%, comps rose 17%, and EPS came in at $2.02, up 37%. The company then bumped up its full-year EPS guidance to a range of $7.50 to $7.74. Bulls point to more shoppers looking for value, keeping stores busy. Bears warn the stock may be pricing in too much good news already and could drop on weaker margins or slower comps. Traders now look to second-quarter sales and any move on guidance as the next big drivers.
Howmet Aerospace trades at a high valuation, tied to demand for aircraft engines, defense, and gas turbines. Shares last changed hands at $264.67, about flat for the session. Its P/E is above 61. First-quarter revenue was up 19% to $2.31 billion, with adjusted EPS jumping 42%. Adjusted EPS strips out some items to get at core profit. Howmet lifted its 2026 outlook as sales climbed 20% in commercial aerospace, 10% in defense, and 39% in gas turbines. Bulls watch for strong pricing and tight aerospace capacity. Bears point out that a premium valuation means trouble if aircraft production stumbles, the supply chain weakens or margins disappoint. The stock looks fully to richly valued, with the next test coming as second-quarter orders and margins hit and the trend in earnings holds up.
Bloom Energy is still the riskiest—maybe the most explosive—stock in this group. Shares last traded at $260.22, up 4.6%. The company’s trailing earnings are still negative, so the P/E doesn’t say much now because profits haven’t normalized. First-quarter revenue soared 130% to $751.1 million. Product revenue was up 208%. Bloom also lifted its 2026 revenue-growth target midpoint to roughly 80%, up from about 60%. Demand for electricity is becoming a big theme as AI data centers and electrification push U.S. power usage to new highs. Bulls see Bloom taking a key role as an on-site power provider for data centers. Bears say with the stock up nearly 200% this year, any hiccup—missed orders, slipping margins, funding worries—could spark a steep drop. The next big catalyst is whether Bloom can land new large-scale data-center power deals and prove that fast revenue growth will start producing steady cash.
Krystal Biotech trades on its rare-disease drug business, not broad economic trends. Shares last changed hands at $317.97, off 1.1%, carrying a P/E around 42.6. Krystal posted first-quarter VYJUVEK sales of $116.4 million, up 32%, with a 95% gross margin. The company reported around $1.0 billion in cash and investments. Bulls see room for the rare-disease unit to widen high-margin profits overseas, but bears point to classic biotech risk — clinical hiccups, regulation, or drug pricing could hit valuation fast. Key milestones are registrational trial results and European pricing or launch news expected in 2026. Krystal appeals to growth investors comfortable with sharp moves around events, but it’s a tougher hold for others.
Viking Holdings shares slipped 1.1% to $92.25 after the company posted first-quarter revenue of $1.05 billion, up 17.5%. Adjusted EBITDA jumped 43.9% to $104.8 million. Adjusted EBITDA strips out interest, taxes, depreciation, amortization and some nonrecurring items, the company said. Viking said as of May 3, 92% of 2026 capacity is sold and 38% of 2027 capacity is booked. Advance bookings for 2027 are tracking 31% higher from a year earlier. Bulls see ongoing demand for higher-end travel, but bears note cyclical risks—cruise names can sell off fast if fuel prices spike, routes get hit by geopolitical shocks, or consumer appetite fades. Investors are watching the pace of summer bookings under new CEO Leah Talactac. Viking is seen more as a tactical momentum idea now, not a deep value bet.
Ross and Howmet look like the more straightforward “buy” names next week, since both posted gains tied to rising earnings and higher forecasts. Bloom and Krystal are riskier plays, with bigger possible upside if their growth story holds, but more downside if expectations slip. Viking sits between them—solid travel momentum but vulnerable to bigger swings if the macro picture changes. The real test comes as trading starts up again: if these stocks can keep their breakouts going. If not, breakouts that fail tend to see investors exit, judging that future earnings growth may already be priced in.
